|
|
|
Venetoclax (7)
|
Venclyxto®
|
AbbVie Deutschland GmbH & Co. KG
|
Oncological diseases
|
Chronic lymphocytic leukaemia, first-line treatment, combination of acalabrutinib with or without obinutuzumab
|
n.d.
|
active procedure
|
|
|
|
Venetoclax (6)
|
Venclyxto®
|
AbbVie Deutschland GmbH & Co. KG
|
Oncological diseases
|
Chronic lymphocytic leukaemia, first-line treatment, combination with ibrutinib
|
n.d.
|
active procedure
|
|
|
|
Venetoclax (5)
|
Venclyxto®
|
AbbVie Deutschland GmbH & Co. KG
|
Oncological diseases
|
Acute myeloid leukaemia (AML), combination therapy, first-line
|
560–840
|
100%
Hint for
considerable additional benefit
|
|
|
|
Venetoclax (4)
|
Venclyxto®
|
AbbVie Deutschland GmbH & Co. KG
|
Oncological diseases
|
Chronic lymphocytic leukaemia (CLL), first-line, in combination with obinutuzumab
|
3,090–3,099
|
100%
additional benefit not proven
|
|
|
|
Venetoclax (2)
|
Venclyxto®
|
AbbVie Deutschland GmbH
|
Oncological diseases
|
Chronic lymphocytic leukaemia (CLL), combination with rituximab
|
2,000–7,200
|
37%
Indication of
minor additional benefit
|
|
|
|
Venetoclax (3)
|
Venclyxto®
|
AbbVie Deutschland GmbH
|
Oncological diseases
|
Chronic lymphocytic leukaemia (CLL), monotherapy
|
300–700
|
100%
additional benefit not proven
|
|
|
|
Venetoclax (1)
|
Venclyxto®
|
AbbVie Deutschland GmbH
|
Oncological diseases
|
Chronic lymphocytic leukaemia (CLL), monotherapy
|
0
300–700
|
100%
non-quantifiable additional benefit
Orphan
repealed
|
